How are pharma companies improving deal readiness amid the 2026 M&A rebound?

Pharma mergers and acquisitions are picking up as companies seek to replace revenue lost to patent expirations, but many remain unprepared for rapid diligence. Experts emphasize that clean financials, current audits, and defensible IP are now essential for maintaining deal value and investor confidence.